Cite Filings / IRD / 0002012383-26-003823
Feed Companies Filings Check
Sign in
SCHEDULE 13G

Statement of Beneficial Ownership

Opus Genetics, Inc. · Filed 2026-10-27 · Acc 0002012383-26-003823

Documents 1

  • SCHEDULE 13G Statement of Beneficial Ownership , xslSCHEDULE_13G_X02/primary_doc.xml

Around this filing

  • 2026-11-16 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-10-27 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-10-27 4 Chief Operating Officer sold 4,767 shares at $3.57 ($16,994)
  • 2026-10-27 4 President sold 33,189 shares at an average $3.54 ($117,365)
  • 2026-10-27 4 Chief Financial Officer sold 14,000 shares at $3.55 ($49,650)
  • 2026-10-27 4 Chief Executive Officer sold 9,591 shares at $3.59 ($34,384)
  • 2026-05-15 SCHEDULE 13G Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · Caligan Partners LP 6.2%
  2. 2026-11-16 SCHEDULE 13G · Boxer Capital Management, LLC 5.4%
  3. 2026-11-16 SCHEDULE 13G/A · Perceptive Advisors LLC 9.99%
  4. 2026-11-16 SCHEDULE 13G · Cormorant Asset Management, LP 6.61%
  5. 2026-11-16 SCHEDULE 13G/A · BALYASNY ASSET MANAGEMENT L.P. 7.36%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…